Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cyclodextrin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Monash University
Deal Size : Inapplicable
Deal Type : Inapplicable
Cyclarity Therapeutics Secures Approval for First-in-Human Clinical Trial
Details : UDP-003 is a first-in-class drug; a specially engineered cyclodextrin which will target and remove toxic oxidized cholesterol, a key driver of acute coronary syndrome.
Product Name : UDP-003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Cyclodextrin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Monash University
Deal Size : Inapplicable
Deal Type : Inapplicable
LOOKING FOR A SUPPLIER?